AKT1 and breast carcinoma: The activated receptor EphA2‐ErbB2 complex consequently recruits signaling molecules and activates MAPK and PI3K/Akt signaling cascades,12 and PI3K/Akt and MAPK pathway activation was related to drug resistance in breast cancer and its inhibitors provided a new effective drug discovery strategy.22, 25